Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sau Yee

Emergency Medicine Englewood, NJ Medical Doctor

NPI 1740288570 CMS profile 351111

245 Engle St, Englewood, NJ 07631

Open in the dashboard

General payments

$4,256

177 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sau Yee of Englewood, NJ is reported in the CMS Open Payments database as having received $4,256 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $807 30
2024 General $1,067 39
2023 General $1,128 31
2022 General $488 28
2021 General $376 26
2020 General $226 11
2019 General $164 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sau Yee
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Sau Yee were reported at $807. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Sau Yee Emergency Medicine median Middle half National median
2019 $164 $51 $18–$128 $163
2020 $226 $29 $16–$99 $114
2021 $376 $40 $18–$124 $132
2022 $488 $49 $20–$134 $149
2023 $1,128 $51 $22–$142 $160
2024 $1,067 $52 $22–$150 $164
2025 $807 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,250 48 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $464 4 payments
  3. GlaxoSmithKline, LLC. $398 9 payments
  4. AstraZeneca Pharmaceuticals LP $339 7 payments
  5. Novo Nordisk Inc $308 19 payments
  6. Lilly USA, LLC $274 17 payments
  7. Optos, Inc. $226 10 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $131 9 payments
  9. Pfizer Inc. $128 8 payments
  10. Exact Sciences Corporation $101 4 payments
  11. Other $637 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,194 173 payments
  2. Education $43 3 payments
  3. Honoraria $20 1 payment
Products named General payments · program years 2019–2025
  1. Otezla $877 45 payments
  2. Repatha Cardiology $712 35 payments
  3. REPATHA Cardiovascular $275 10 payments
  4. AIRSUPRA $265 3 payments
  5. JARDIANCE Diabetes $246 2 payments
  6. JARDIANCE Diabetes $218 2 payments
  7. AREXVY $200 2 payments
  8. P200DTx $170 7 payments
  9. P200TxE $170 7 payments
  10. P200T $170 7 payments
  11. Other $2,808 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,918

Median for Pediatric Medicine: 38

Drug cost

$301,826

Median for Pediatric Medicine: $2,769

Branded share of claims

19.3%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 83 $101,121
Mounjaro Tirzepatide Brand 30 $38,264
Rybelsus Semaglutide Brand 18 $35,783
Januvia Sitagliptin Phosphate Brand 17 $25,287
Ozempic Semaglutide Brand 19 $23,516
Nurtec Odt Rimegepant Sulfate Brand 11 $20,747
Repatha Sureclick Evolocumab Brand 11 $11,470
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 11 $5,641
Rosuvastatin Calcium Generic 191 $4,029
Atorvastatin Calcium Generic 265 $3,028

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$57,785

Of which drugs: $4,730

Medicare patients

109

Average age 65

Services billed

811

60 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Diabetes 34%
Arthritis 30%
Ischemic heart disease 17%
Depression 16%
Cancer 13%
COPD 12%
Chronic kidney disease 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 27 27 $2,209
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 13 13 $285

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $194
$194 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $132
$132 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $125
$125 83 —
AREXVY
  • GlaxoSmithKline, LLC. $120
$120 — —
Repatha
  • Amgen Inc. $69
$69 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record